PR Newswire
London, August 8
Director/PDMR Shareholding
August 8, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated them | ||
| a) | Name | Kim Stratton | |
| 2. | Reason for the notification | ||
| a) | Position / status | Head of International Commercial | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Acceptance of Restricted Stock Units in respect of notional Ordinary Shares awarded under the Shire Long Term Incentive Plan 2015 in recognition of promotion to Executive Committee membership. Subject to continued service, 50% of the award will vest on August 5, 2018, and 50% will vest on August 5, 2019. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 6,149 | ||
| d) | Aggregated information | N/A (single transaction) | |
| e) | Date of the transaction | August 5, 2016 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1. | Details of the person discharging managerial responsibilities / person closely associated them | ||
| a) | Name | Perry Sternberg | |
| 2. | Reason for the notification | ||
| a) | Position / status | Head of US Commercial | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares ("ADSs") | |
| Identification code | ISIN: US82481R1068 | ||
| b) | Nature of the transaction | Acceptance of Restricted Stock Units in respect of notional ADSs awarded under the Shire Long Term Incentive Plan 2015 in recognition of promotion to Executive Committee membership. Subject to continued service, 50% of the award will vest on August 5, 2018, and 50% will vest on August 5, 2019. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 1,998 | ||
| d) | Aggregated information | N/A (single transaction) | |
| e) | Date of the transaction | August 5, 2016 | |
| f) | Place of the transaction | Outside a trading venue | |
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
